Arbutus Biopharma Corp., of Vancouver, British Columbia, and Gritstone Oncology Inc., of San Francisco, entered a collaboration and licensing agreement in which Arbutus will deploy its lipid nanoparticle (LNP) technology to deliver Gritstone's RNA-based neoantigen immunotherapy products.